relma-cel
jw therapeutics
['lymsm', 'car t', 'nhl', 'jw']
the car t-cell therapy relma-cel (jwcar029) was well-tolerated and yielded promising response and survival rates in patients with b-nhl, according to new data from a phase 1 study (nct03344367). #lymsm #asco22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.